Sugi Predict

Sugi Predict / Compounds / SCHEMBL2035189

SCHEMBL2035189

SCHEMBL2035189

CN[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 10/20 0.67
▸ MME P08473 1/20 0.63
▸ ACE P12821 1/20 0.63
▸ CPA1 P15085 1/20 0.63
▸ ACE2 Q9BYF1 1/20 0.63
▸ GPR34 Q9UPC5 4/20 0.62
▸ MMP9 P14780 1/20 0.62
▸ MMP8 P22894 1/20 0.62
▸ PPARA Q07869 3/20 0.60
▸ LTA4H P09960 1/20 0.57
▸ PPARD Q03181 1/20 0.57
▸ GPR132 Q9UNW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030203 1.00 PPARG (0.67) PPARGMMEACECPA1ACE2
SCHEMBL8760872 1.00 PPARG (0.67) PPARGMMEACECPA1ACE2
SCHEMBL684726 0.90 PPARG (0.62) PPARGMMEACECPA1ACE2
SCHEMBL13227760 0.90 PPARG (0.62) PPARGMMEACECPA1ACE2
SCHEMBL13013217 0.90 PPARG (0.62) PPARGMMEACECPA1ACE2
SCHEMBL23901567 0.89 LTA4H (0.61) PPARGMMEACECPA1ACE2
SCHEMBL3499760 0.89 LTA4H (0.65) PPARGMMEACECPA1ACE2
SCHEMBL3499757 0.89 LTA4H (0.65) PPARGMMEACECPA1ACE2
SCHEMBL681310 0.88 MMP9 (0.59) PPARGMMEACECPA1ACE2
SCHEMBL10272198 0.88 MMP9 (0.59) PPARGMMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 — — US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 — — US disclosed
WO-2021067439-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 — — WO disclosed
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2021-04-01 — — US disclosed
CN-112321677-A Nannocystin A analogue and preparation method and application thereof 北京大学深圳研究生院 2021-02-05 — — CN disclosed
US-10633630-B2 Acceleration of Mycobacterium growth ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2020-04-28 — — US disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 — — US disclosed
EP-3158053-B1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) 2019-03-13 — — EP disclosed
US-9707282-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-18 — — US disclosed
US-20170121672-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2017-05-04 — — US disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 — — US disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 — — EP disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 — — WO disclosed
US-6916812-B2 Dietetic agents BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-12 — — US disclosed
US-20030232807-A1 Alpha-aminoamide derivatives as melanocortin agonists POINDEXTER GRAHAM S (US) 2003-12-18 — — US disclosed
EP-0767800-A1 HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE WARNER-LAMBERT COMPANY (US) 1997-04-16 — — EP disclosed
EP-0725790-A1 SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE PARKE DAVIS & COMPANY (US) 1996-08-14 — — EP disclosed
WO-1996000736-A1 HISTIDINE AND HOMOHISTIDINE DERIVATIVES AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE WARNER-LAMBERT COMPANY (US) 1996-01-11 — — WO disclosed
WO-1995011917-A1 SUBSTITUTED TETRA- AND PENTAPEPTIDE INHIBITORS OF PROTEIN:FARNESYL TRANSFERASE PARKE, DAVIS & COMPANY (US) 1995-05-04 — — WO disclosed
EP-0030845-A2 Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them ELI LILLY AND COMPANY (US) 1981-06-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof RICTOR, FKBP14, MTOR PPARG 2207/4885MME 3786/4885ACE 4369/4885
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR PPARG 2207/4885MME 3786/4885ACE 4369/4885
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR PPARG 2207/4885MME 3786/4885ACE 4369/4885
US-20210094933-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RICTOR, FKBP14, MTOR PPARG 2207/4885MME 3786/4885ACE 4369/4885
US-20030232807-A1 Alpha-aminoamide derivatives as melanocortin agonists MC1R, MC5R, MC4R PPARG 528/4885MME 438/4885ACE 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.